Induction regimens for transplant-eligible patients with newly diagnosed multiple myeloma: a network meta-analysis of randomized controlled trials.

about

Enhanced recovery programs in lung cancer surgery: systematic review and meta-analysis of randomized controlled trials.Long-Term Efficacy of Maintenance Therapy for Multiple Myeloma: A Quantitative Synthesis of 22 Randomized Controlled Trials.

P2860

Q45397769-B0475A35-6A79-4419-A389-1A758EA5FDF6 Q55285098-0AF6AF22-EB40-42C9-A830-8932BC57BBEC

P2860

Induction regimens for transplant-eligible patients with newly diagnosed multiple myeloma: a network meta-analysis of randomized controlled trials.

Item

http://www.wikidata.org/entity/Q38661374

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Induction regimens for transpl ...... randomized controlled trials.

@en

type

Item

label

Induction regimens for transpl ...... randomized controlled trials.

@en

prefLabel

Induction regimens for transpl ...... randomized controlled trials.

@en

P1476

Induction regimens for transpl ...... randomized controlled trials.

@en

P2093

Jia-Feng Chen

http://www.w3.org/2001/XMLSchema#string

Ling-Fei Xiao

http://www.w3.org/2001/XMLSchema#string

Ran Zhang

http://www.w3.org/2001/XMLSchema#string

Xiang-Yu Meng

http://www.w3.org/2001/XMLSchema#string

Yi-Xuan Li

http://www.w3.org/2001/XMLSchema#string

Zi-Hang Zeng

http://www.w3.org/2001/XMLSchema#string

P2860

Measuring inconsistency in meta-analyses

Practical methods for incorporating summary time-to-event data into meta-analysis

A phase 2 study of bortezomib in relapsed, refractory myeloma.

Bortezomib-thalidomide-based regimens improved clinical outcomes without increasing toxicity as induction treatment for untreated multiple myeloma: a meta-analysis of phase III randomized controlled trials.

VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial.

Antitumor activity of thalidomide in refractory multiple myeloma.

Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves.

Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma.

International uniform response criteria for multiple myeloma.

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.

P304

287-298

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/CMAR.S138932

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28744159

http://www.w3.org/2001/XMLSchema#string

P932

5513856

http://www.w3.org/2001/XMLSchema#string

Induction regimens for transplant-eligible patients with newly diagnosed multiple myeloma: a network meta-analysis of randomized controlled trials.

about

P2860

P2860

Induction regimens for transplant-eligible patients with newly diagnosed multiple myeloma: a network meta-analysis of randomized controlled trials.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P932